RecruitingNot ApplicableNCT04271878

Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome


Sponsor

University of Calgary

Enrollment

26 participants

Start Date

Feb 2, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The mechanism behind postural orthostatic tachycardia syndrome (POTS) involves many causes including a sympathetic nervous system problem. Blood gases, like carbon dioxide (CO2), have an important effect on sympathetic activation. The purpose of this research study is to determine if higher CO2 levels have any effect in lowering heart rate and reducing POTS symptoms when upright/standing. The investigators are also searching for the ideal CO2 concentration to achieve the most effective response


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria6

  • Physician diagnosis of Postural Tachycardia Syndrome (POTS)
  • Age 18-60 years
  • Male and Female
  • Non - smokers.
  • Able and willing to provide informed consent.
  • Ability to travel to Libin Cardiovascular Institute of Alberta Autonomic Testing Lab at the University of Calgary, Calgary, AB.

Exclusion Criteria7

  • Overt cause for postural tachycardia, i.e., acute dehydration
  • Participants with somatization or severe anxiety symptoms will be excluded
  • Pregnant
  • Inability to tolerate mask for the duration of the study
  • Subjects who require portable oxygen at rest or with exercise
  • Subjects with chronic heart failure or severe pulmonary disease who are unable to climb one flight of stairs due to shortness of breath.
  • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRespirAct™ system (Thornhill Research Inc., Toronto, Canada)

1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied) 2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels 3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg ) 4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg) 5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied 6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels.


Locations(1)

University of Calgary

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04271878


Related Trials